Compare BioNano Genomics Inc (BNGO) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Procter & Gamble Co — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Procter & Gamble Co trades at $144.18 (market cap $337.53B). The key difference: Procter & Gamble Co is far larger — about 24709.4× BioNano Genomics Inc's market cap, and Procter & Gamble Co pays a 3% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PG | |
|---|---|---|
Market Cap | $13.66M | $337.53B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $167.18 |
52-Week Low | $1.06 | $138.10 |
Enterprise Value | $16.26M | $363.37B |
Volume | — | 6,423,436 |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Procter & Gamble (PG) trades at $144.35, down 1.39% over the past day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $84.28B for 2025 with a net income margin of 18.44%, and has beaten EPS estimates in recent quarters. Analyst consensus is a Buy with a $161.20 price target, though recent news highlights concerns over its premium valuation amid modest growth expectations.
PG offers stable fundamentals and a strong dividend history, but faces risks from competitive pressures and economic sensitivity. The stock's near-term upside may be capped by its high P/E of 21.94, while long-term investors could benefit from its consistent profitability and brand strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
